Name: | Degarelix |
---|---|
Item Code: | HG013 |
CAS Number: | 214766-78-6 |
Other name: | Degarelix |
Molecular formula: | C82H103ClN18O16 |
Molecular mass: | 1632.28 |
Sequence: | Ac-D-2-Nal-D-4-Cpa-D-3-Pal-Ser-4-amino-Phe(L-hydroorotyl)-4-ureido- D-Phe-Leu-Lys(isopropyl)-Pro-D-Ala-NH2 |
Purity: | >98% |
Main usage: | Advanced hormone-dependent prostate carcinoma |
Product Description
Degarelix Acetate is an LHRH (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Degarelix reversibly and dose-dependently suppresses gonadotropin and sex steroid levels by inhibiting the binding of endogenous LHRH to its receptors.
Degarelix showed to be at least as effective as leuprolide in sustaining levels of testosterone that are equivalent to or lower than that seen with castration.
【Test】 | 【Specifications】 |
Appearance | White to off-white powder |
Identification By HPLC | Retention time is same with the reference substance |
Molecular Ion Mass | 1632.28±1 |
Amino Acid Composition | ±20% |
Purity (HPLC) : | ≥ 98% |
Related Substances(HPLC) | Total impurities <2.0% Single impurity: <1.0% |
Acetic acid (HPLC) | < 10.0% |
Water Content(Karl Fischer) : | ≦6.0 % |
Peptide Content : | NLT 80% |
Residual Solvents(Acetonitrile) | ≦0.041% |
Assay(By Anhydrous, Acetic Acid-free) | 95.0~105.0% |
Bacterial Endotoxins : | ≦5EU/mg |